Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 18/20 | 0.55 |
| ▸ | PPARA | Q07869 | 17/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9656236 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL4820511 | 0.95 | SMN1; SMN2 (0.59) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL5405854 | 0.92 | SMN1; SMN2 (0.60) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL11550284 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL8935859 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL8935844 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL1171344 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL21991991 | 0.85 | PPARG (0.66) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL1745447 | 0.85 | PPARG (0.66) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL16242008 | 0.85 | PPARG (0.66) | SMN1; SMN2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7041684-B2 | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20020165234-A1 | Selective B3 adrenergic agonists | CROWELL THOMAS A (US) | 2002-11-07 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-0827746-B1 | Carbazole analogues as selective beta3 adrenergic agonists | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0904269-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-03-31 | — | — | EP | disclosed |
| US-5871709-A | TETRAAZACYCLODODECANE COMPOUNDS SUBSTITUTED WITH ALKYL CARBOXY COMPOUNDS FOR CARDIOVASCULAR DISORDERS AND BRAIN TUMORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-02-16 | — | — | US | disclosed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998009625-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0827746-A1 | Carbazole analogues as selective B3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1997016435-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | disclosed |
| US-5277895-A | Nuclear magnetic resonance | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-11 | — | — | US | disclosed |
| WO-1991002714-A1 | AUTOMATED PEPTIDE DESIGN AND SYNTHESIS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | SMN1; SMN2 3203/4885PPARG 278/4885PPARA 335/4885 |
| US-20020165234-A1 | Selective B3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | SMN1; SMN2 3246/4885PPARG 189/4885PPARA 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.